Skip to main content
Premium Trial:

Request an Annual Quote

MiRagen Hits First Milestone in Servier microRNA Drug Partnership

Premium

MiRagen Therapeutics this week said it has achieved the first milestone in its partnership with Les Laboratoires Servier, with the French company selecting a third target for microRNA drug development.

The move triggered an undisclosed milestone payment to MiRagen.

In late 2011, the companies agreed to jointly develop two of MiRagen’s miRNA antagonists including one designed to silence miR-208 for chronic heart failure and one that targets miR-15/miR-195 to treat post-myocardial infarction remodeling (GSN 11/20/2011).

That deal, which is valued for MiRagen at $45 million over three years — and could be worth up to $1 billion if all clinical and commercial milestones are met — also gave Servier the option to a yet-to-be-named third drug candidate. Now Servier has selected the drug target for that third compound.

Additional details were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.